Frontage Holdings Corporation (FGHQF) Research

Frontage Holdings Corporation operates as a contract research organization, furnishing an extensive array of laboratory and associated services to pharmaceutical, biotechnology, and agrochemical firms, in addition to conducting bioequivalence studies. Its service portfolio includes laboratory testing, covering method development, validation, sample analysis, and central laboratory functions. The company also delivers chemistry, manufacturing, and control (CMC) services, which involve assisting with drug product development and analysis, alongside the provision and supply of materials for clinical trials. Furthermore, Frontage offers drug metabolism and pharmacokinetic (DMPK) services, encompassing study design, execution, and data interpretation, from early discovery structural optimization to pharmacokinetic assessments in rodents and non-GLP bioanalytical studies. Its expertise extends to safety and toxicology, performed through both in-vitro and in-vivo studies. The company also handles bioequivalence services, managing their design, coordination, and reporting, as well as general chemistry services like contract research and custom synthesis. Lastly, clinical services are provided, including early-stage trials, bioequivalence/bioavailability (BE/BA) studies, biometrics, and data management. Established in 2018 and headquartered in Exton, Pennsylvania, Frontage maintains a global presence, operating in the United States, the People's Republic of China, Europe, India, Japan, South Korea, and Australia. It functions as a subsidiary of Hongkong Tigermed Co., Limited.

Open Frontage Holdings Corporation (FGHQF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.